Promising preclinical data suggest that strategies combining MAPK and PI3K inhibitors may similarly prove beneficial in NRAS- and NF1-driven melanoma (Petit et al., 2019; Posch et al., 2013). This evidence concerns the gene NRAS and melanoma.